Analyzing Sarepta Therapeutics Inc (NASDAQ: SRPT)’s Stock Performance and Future Prospects

In the latest trading session,, 0.62 million Sarepta Therapeutics Inc (NASDAQ:SRPT) shares changed hands as the company’s beta touched 0.47. With the company’s most recent per share price at $17.05 changed hands at -$0.06 or -0.35% at last look, the market valuation stands at $1.68B. SRPT’s current price is a discount, trading about -855.72% off its 52-week high of $162.95. The share price had its 52-week low at $16.97, which suggests the last value was 0.47% up since then. When we look at Sarepta Therapeutics Inc’s average trading volume, we note the 10-day average is 11.78 million shares, with the 3-month average coming to 5.22 million.

Analysts gave the Sarepta Therapeutics Inc (SRPT) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.07. If we narrow down to specifics, the data shows that 1 out of 17 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 6 recommended SRPT as a Hold, 10 felt it is a Buy and 0 rated the stock as Underweight.

Sarepta Therapeutics Inc (NASDAQ:SRPT) trade information

Instantly SRPT was in red as seen in intraday trades today. With action -9.64%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -89.13%, with the 5-day performance at -9.64% in the red. However, in the 30-day time frame, Sarepta Therapeutics Inc (NASDAQ:SRPT) is -55.84% down. Looking at the short shares, we see there were 9.89 million shares sold at short interest cover period of 2.61 days.

The consensus price target for the stock as assigned by Wall Street analysts is 70, meaning bulls need an upside of 75.64% from its recent market value. According to analyst projections, SRPT’s forecast low is 10 with 110 as the target high. To hit the forecast high, the stock’s price needs a -545.16% plunge from its current level, while the stock would need to tank 41.35% for it to hit the projected low.

The 2025 estimates are for Sarepta Therapeutics Inc earnings to decrease by -272.65%, but the outlook for the next 5-year period is at 19.75% per year.

SRPT Dividends

Sarepta Therapeutics Inc is expected to release its next quarterly earnings report on 2025-May-06.

Sarepta Therapeutics Inc (NASDAQ:SRPT)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 4.44% of Sarepta Therapeutics Inc shares while 90.25% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 94.45%. There are 90.25% institutions holding the Sarepta Therapeutics Inc stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 10.9117% of the shares, roughly 10.32 million SRPT shares worth $1.63 billion.

VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 9.5496% or 9.04 million shares worth $1.43 billion as of 2024-06-30.

Among Mutual Funds, the top two as of Mar 31, 2025 were GROWTH FUND OF AMERICA and iShares Trust-iShares Core S&P Mid-Cap ETF . With 3.15 shares estimated at $53.86 million under it, the former controlled 3.21% of total outstanding shares. On the other hand, iShares Trust-iShares Core S&P Mid-Cap ETF held about 3.15% of the shares, roughly 3.09 shares worth around $52.89 million.

Marketing Sentinel
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.